Efficacy and Safety of Lenalidomide in Combination With Cyclosporine A in Patients With Myelodysplastic Syndromes
A Single-Arm, Open-Label Study of the Efficacy and Safety of Lenalidomide in Combination With Cyclosporine A in Patients With Red Blood Cell Transfusion-Dependent Myelodysplastic Syndromes
Sponsor: Celgene
Terminated
Lack of efficacy.
Other terminated trials from Celgene
Other Myelodysplastic Syndrome trials with similar outcome
Listed as NCT00840827, this PHASE2 trial focuses on Myelodysplastic Syndrome and remains terminated or withdrawn. Sponsored by Celgene, it has been updated 7 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Dec 2019 — Jan 2021 [monthly]
Terminated PHASE2
Status: Completed → Terminated
-
Jun 2018 — Dec 2019 [monthly]
Completed PHASE2
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Dec 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Celgene
- Weill Medical College of Cornell University
For direct contact, visit the study record on ClinicalTrials.gov .